key: cord-0696547-rxh50ore
authors: Patra, Ritwik; Chandra Das, Nabarun; Mukherjee, Suprabhat
title: Targeting human TLRs to combat COVID‐19: A solution?
date: 2020-08-13
journal: J Med Virol
DOI: 10.1002/jmv.26387
sha: 18a0e9760835998f41b73ba45d11d91f361c7d24
doc_id: 696547
cord_uid: rxh50ore

Toll-like receptors (TLRs) are the pivotal mediators and regulators of host immunity. Influence of different TLRs in the immunity and immunopathology of COVID-19 infection has been demonstrated recently. Interestingly, a number of TLR agonists and antagonists currently undergoing through different phases of clinical trial usher to be a hope for us. Herein, we present the therapeutic potential of TLR-targeted intervention strategies including development of drugs and vaccines against SARS-CoV-2. This article is protected by copyright. All rights reserved.

In this fast-spreading pandemic situation of COVID-19, more than six lakhs peoples have died till date. The appropriate therapeutic treatment strategy, drug, or vaccine is still not available. Current clinical data manifests that the severity is due to the cytokine storm and overt immuno-pathogenesis, causing inflammation in the lungs particularly at the alveolar tissue. 2,3 Activation of the human innate immune cells (macrophages, dendritic cells) through the binding of PAMP from SARS-Cov-2 to cell surface TLRs have been demonstrated to be a vital mediator of COVID-19 immunopathogenesis. 4 Signaling pathways originated from TLR4 and TLR5 leading to the activation of mitogenactivated protein kinases and/or nuclear factor-κB induces the expression of proinflammatory cytokines. 5 Particularly in SARS-CoV-2 infection, major immunopathological consequences leading to death have resulted from the interaction of the SARS-CoV-2 antigens and human TLRs. 6, 7 Precisely, viral spike protein binds with the extracellular domain of various TLRs including TLR1, TLR4, and TLR6, with the strongest binding with TLR4. 1 Considering the immense importance in the disease biology of COVID-19, TLR-SARS-CoV-2 interaction appears to be a suitable target for the conception of appropriate therapeutic strategy against the pandemic.

F I G U R E 1 Therapeutic strategies for targeting Toll-Like receptors (TLRs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). IFN, interferon; IL, interleukin; NF-κB, nuclear factor κB 

Adjunct immunotherapies for the management of severely ill COVID-19 patients

Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease

Hypothesis SARS-CoV-2 and viral sepsis: observations and hypotheses

TLR polymorphism in host immune response to infectious diseases: a review

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

COVID-19: towards understanding of pathogenesis

Toll-like receptors: promising therapeutic targets for inflammatory diseases

TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review

Design of a peptidebased subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog

Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach